Evidence map›Paper›PMID 38708932›Full record

SynthesisJournal of clinical hypertension (Greenwich, Conn.)2024

A meta-analysis of left ventricular dysfunction in ankylosing spondylitis.

Olayiwola Bolaji, Osejie Oriaifo, Olanrewaju Adabale, Arthur Dilibe, Krishna Kuruvada, Faizal Ouedraogo, Ebubechukwu Ezeh, Ambica Nair, Titilope Olanipekun, Sula Mazimba and 1 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A meta-analysis of left ventricular dysfunction in ankylosing spondylitis.Journal of clinical hypertension (Greenwich, Conn.) · 2024
    Pooled it
  2. Article
  3. Heart failure in autoimmune rheumatic diseases.Rheumatology international · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olayiwola BolajiDepartment of Internal Medicine, Rutgers University New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-6314-2071
Osejie OriaifoDepartment of Internal Medicine, ECU Health Medical Center, Greenville, North Carolina, USA.
Olanrewaju AdabaleDepartment of Internal Medicine, ECU Health Medical Center, Greenville, North Carolina, USA.
Arthur DilibeDepartment of Internal Medicine, ECU Health Medical Center, Greenville, North Carolina, USA.
Krishna KuruvadaDepartment of Internal Medicine, University of Maryland Capital Region Health, Largo, Maryland, USA.
Faizal OuedraogoDepartment of Internal Medicine, University of Maryland Capital Region Health, Largo, Maryland, USA.
Ebubechukwu EzehDepartment of Cardiovascular Disease, The University Of Kansas Medical Center, Kansas City, Kansas, USA.
Ambica NairOcean Medical Center Brick, Brick, New Jersey, USA.
Titilope OlanipekunBrigham and Women's Hospital Department of Medicine Boston, Boston, Massachusetts, USA.
Sula MazimbaAdvanced Heart Failure and Transplant Cardiology, AdventHealth Medical Group Transplant Institute, Orlando, Florida, USA.
Chadi AlraiesCardiovascular Institute, Detroit Medical Center, DMC Heart Hospital, Detroit, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the spine, presenting a considerable morbidity risk. Although evidence consistently indicates an elevated risk of ischemic heart disease among AS patients, debates persist regarding the likelihood of these patients developing left ventricular dysfunction (LVD). Our investigation aimed to determine whether individuals with AS face a greater risk of LVD compared to the general population. To accomplish this, we identified studies exploring LVD in AS patients across five major databases and Google Scholar. Initially, 431 studies were identified, of which 30 met the inclusion criteria, collectively involving 2933 participants. Results show that AS patients had: (1) poorer Ejection Fraction (EF) [mean difference (MD): -0.92% (95% CI: -1.25 to -0.59)], (2) impaired Early (E) and Late (atrial-A) ventricular filling velocity (E/A) ratio [MD: -0.10 m/s (95% CI: -0.13 to -0.08)], (3) prolonged deceleration time (DT) [MD: 12.30 ms (95% CI: 9.23-15.36)] and, (4) a longer mean isovolumetric relaxation time (IVRT) [MD: 8.14 ms (95% CI: 6.58-9.70)] compared to controls. Though AS patients show increased risks of both systolic and diastolic LVD, we found no significant differences were observed in systolic blood pressure [MD: 0.32 mmHg (95% Confidence Interval (CI): -2.09 to 2.73)] or diastolic blood pressure [MD: 0.30 mmHg (95% CI: -0.40 to 1.01)] compared to the general population. This study reinforces AS patients' susceptibility to LVD without a notable difference in HTN risk.

Indexed as

Spondylitis, AnkylosingStroke VolumeVentricular Dysfunction, LeftAdultAgedEchocardiographyFemaleHumansMaleMiddle AgedRisk Factorsankylosing spondylitiscardiovascular diseasehypertension (HTN)inflammatory arthritisleft ventricular dysfunction

Identifiers

PMID38708932
PMCPMC11232451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.